Acute-phase protein response and survival duration of patients with pancreatic cancer
- 15 April 1995
- Vol. 75 (8), 2077-2082
- https://doi.org/10.1002/1097-0142(19950415)75:8<2077::aid-cncr2820750808>3.0.co;2-9
Abstract
Background. Current methods to predict survival duration of patients with pancreatic cancer are limited. The aim of this study was to determine whether certain nutritional indices and the acute-phase protein response are prognostic factors independent of disease stage for patients with unresectable pancreatic cancer. Methods. Variables at the time of diagnosis of 102 patients with unresectable pancreatic cancer were entered into a Cox's proportional hazards model. Included in the analysis were the serum concentration of C-reactive protein (CRP) and albumin, the extent of weight loss, age, sex, and disease stage (International Union Against Cancer criteria). Results. A multivariate analysis in which each factor was adjusted for the influence of the other factors revealed the patient age, disease stage, serum albumin, and serum CRP to be independent predictors of survival. The presence of an acute-phase protein response was the most significant independent predictor of survival duration. The median survival of those with an acute-phase protein response (CRP > 10 mg/L, n = 45) was 66 days compared with 222 days for those with no acute-phase protein response (n = 57, P = 0.001, Mann-Whitney U test). Conclusion. The acute-phase protein response is a useful prognostic indicator for patients with unresectable pancreatic cancer. Moreover, the metabolic disturbances associated with an acute-phase protein response of patients with pancreatic cancer may be a worthwhile therapeutic target.Keywords
This publication has 21 references indexed in Scilit:
- Cytokines, the Acute-Phase Response, and Resting Energy Expenditure in Cachectic Patients with Pancreatic CancerAnnals of Surgery, 1994
- The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancerBritish Journal of Cancer, 1994
- Evidence for the involvement of interleukin 6 in experimental cancer cachexia.Journal of Clinical Investigation, 1992
- Anticachectin/tumor necrosis factor‐α antibodies attenuate development of cachexia in tumor modelsThe FASEB Journal, 1989
- Induction of rat acute‐phase proteins by interleukin 6 in vivoEuropean Journal of Immunology, 1988
- Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.The Journal of Experimental Medicine, 1988
- Acute‐Phase Proteins or Tumour Markers: The Role of SAA, SAP, CRP and CEA as Indicators of Metastasis in a Broad Spectrum of Neoplastic DiseasesScandinavian Journal of Immunology, 1984
- Changes in body composition of cancer patients following combined nutritional supportNutrition and Cancer, 1982
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsThe American Journal of Medicine, 1980
- THE IMMEDIATE CAUSES OF DEATH IN CANCERThe American Journal of the Medical Sciences, 1932